Tuberous Sclerosis Complex Clinical Trial
— RAPITOfficial title:
Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
Tuberous sclerosis complex (TSC) is a genetic disease that leads to mental retardation in over 50% of patients, and to learning problems, behavioral problems, autism and epilepsy in up to 90% of patients. The underlying deficit of TSC, loss of inhibition of the mammalian target of rapamycin (mTOR) protein due to dysfunction of the tuberin/hamartin protein complex, can be rescued by everolimus. Everolimus has been registered as treatment for renal cell carcinoma and giant cell astrocytoma (SEGA). Evidence in human and animal studies suggests that mTOR inhibitors improve learning and development in patients with TSC.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | November 2016 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 4 Years to 15 Years |
Eligibility |
Inclusion Criteria: - Children with a definite diagnosis of TSC between 4 and 15 years. - With an IQ estimated <80 and/or special schooling and/or autism spectrum disorder and/or learning disability requiring remedial teaching. - Written informed consent by parents/care-takers, and the patient if he or she is 12 years or older and cognitively able to consent. - In girls after menarche, appropriate contraception must be used or abstinence practiced. Exclusion Criteria: - Hepatic dysfunction - Surgery <6wk - Current infection at time of inclusion - Developmental age estimated below 3.5 years - Intractable epilepsy with more than 1 seizure/week - Inability to comply with the treatment protocol - Additional diseases or disorders that may influence the endpoints, including: - SEGA requiring treatment - Uncontrolled diabetes mellitus - Known impaired lung function - Allergy for any of the components of the study medication - Prior treatment with mTOR inhibitors - HIV seropositivity - Bleeding diathesis or oral anti-vitamin K medication - Serum creatinine > 1.5 x ULN - Uncontrolled hyperlipidemia (fasting serum cholesterol > 7.75 mmol/L, fasting serum triglycerides > 2.5 x ULN) - Use of investigational drug within 30 days prior to inclusion - History of myocardial infarction, angina or stroke related to atherosclerosis, organ transplantation, malignancy in the past 2 years - Pregnancy or breastfeeding - Children at risk for Hepatitis B (HB), unless hepatitis B serology is normal. Risk groups are children who have lived in Asia, Africa, Central and South America, Eastern Europe, Spain, Portugal, and Greece, children with known or suspected past or current hepatitis B infection, current or prior IV illicit drug use, current or prior dialysis, household contact with hepatitis B infected patient(s), current or prior high-risk sexual activity, body piercing or tattoos, mother known to have hepatitis B history. If vaccinated, presence of HBs Ab is normal. - Known or suspected hepatitis C infection, unless hepatitis C serology is normal. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Netherlands | Erasmus Medical Center | Rotterdam |
Lead Sponsor | Collaborator |
---|---|
Erasmus Medical Center | Utrecht University |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | School level | Assessed by the school CITO (centraal instituut voor toetsontwikkeling) scores or reading and arithmetic scores | 12 Months | No |
Other | Pharmacokinetics | Assessed by measuring trough levels of everolimus | 12 Months | Yes |
Other | Safety | Levels of and abnormalities in blood control values | 12 Months | Yes |
Primary | Cognitive ability measured by IQ | Assessed by Wechsler scales: Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III NL) and Wechsler Intelligence Scale for Children (WISC-III-NL) | 12 months | No |
Secondary | Autistic features | Assessed by Autism Diagnostic Observation Schedule (ADOS) | 12 Months | No |
Secondary | Social and communicational skills | Assessed by social responsiveness scale (SRS) and Dutch Children's Communication Checklist (CCC-2-NL) questionnaires | 12 Months | No |
Secondary | Working memory and attention, information processing | Assessed by Cambridge Neuropsychological Test Automated Battery (CANTAB) | 6 and 12 Months | No |
Secondary | Visual-motor integration | Assessed by BEERY Visual-Motor Integration (BEERY VMI), grooved pegboard | 12 Months | No |
Secondary | Child behavior | Assessed by Child Behavior Checklist (CBCL) and Teacher's Report Form (TRF) questionnaires | 12 Months | No |
Secondary | Executive functioning | Assessed by Behavior Rating Inventory of Executive Functioning (BRIEF) questionnaire Dutch version | 12 Months | No |
Secondary | Sleeping problems | Assessed by Sleep Disturbance Scale for Children (SDSC) questionnaire | 12 Months | No |
Secondary | Child health | Assessed by Child Health Questionnaire Parent Form (CHQ-PF50) questionnaire | 12 Months | No |
Secondary | Sensory related difficulties | Assessed by Short Sensory Profile (SSP) questionnaire | 12 Months | No |
Secondary | Epilepsy | Comparison of epilepsy frequency during month previous to study start and last month of trial participation. EEG abnormalities |
12 Months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02687633 -
Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex
|
N/A | |
Completed |
NCT02201212 -
Everolimus for Cancer With TSC1 or TSC2 Mutation
|
Phase 2 | |
Completed |
NCT01767779 -
Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
|
||
Recruiting |
NCT05104983 -
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
|
Phase 2 | |
Recruiting |
NCT02098759 -
Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex
|
N/A | |
Recruiting |
NCT03356769 -
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
|
Phase 2 | |
Recruiting |
NCT04987463 -
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
|
Phase 2/Phase 3 | |
Completed |
NCT05323370 -
Lymphangioleiomyomatosis, a Study on Cathepsin K
|
||
Recruiting |
NCT06392009 -
A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05604170 -
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
|
Phase 3 | |
Completed |
NCT03276195 -
Studies in Patients With Tuberous Sclerosis Complex
|
||
Recruiting |
NCT05059327 -
Basimglurant in Children, Adolescents, and Young Adults With TSC
|
Phase 2 | |
Completed |
NCT02061397 -
Safety of Simvastatin in LAM and TSC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04112537 -
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
|
||
Active, not recruiting |
NCT02962414 -
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
|
Phase 3 | |
Active, not recruiting |
NCT05495425 -
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
|
Phase 3 | |
Active, not recruiting |
NCT05044819 -
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
|
Phase 4 | |
Completed |
NCT01929642 -
Rapalogues for Autism Phenotype in TSC: A Feasibility Study
|
Phase 2 | |
Recruiting |
NCT06160310 -
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
|